Argenx (ARGX)
(Delayed Data from NSDQ)
$393.72 USD
-4.87 (-1.22%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $394.03 +0.31 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
argenex SE (ARGX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$501.35 | $591.00 | $408.00 | 25.78% |
Price Target
Based on short-term price targets offered by 20 analysts, the average price target for argenex SE comes to $501.35. The forecasts range from a low of $408.00 to a high of $591.00. The average price target represents an increase of 25.78% from the last closing price of $398.59.
Analyst Price Targets (20)
Broker Rating
argenex SE currently has an average brokerage recommendation (ABR) of 1.62 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 26 brokerage firms. The current ABR compares to an ABR of 1.62 a month ago based on 26 recommendations.
Of the 26 recommendations deriving the current ABR, 19 are Strong Buy, representing 73.08% of all recommendations. A month ago, Strong Buy represented 73.08%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 19 | 19 | 19 | 19 | 19 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 6 | 6 | 6 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.62 | 1.62 | 1.62 | 1.56 | 1.56 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/1/2024 | Scotiabank | George Farmer | Hold | Hold |
3/1/2024 | Robert W. Baird & Co. | Joel L Beatty | Strong Buy | Strong Buy |
3/1/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
3/1/2024 | JMP Securities | Jason N Butler | Not Available | Strong Buy |
2/16/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
12/21/2023 | Piper Sandler | Allison M Bratzel | Strong Buy | Strong Buy |
12/21/2023 | Evercore Partners | Gavin Clark-Gartner | Strong Buy | Strong Buy |
12/20/2023 | William Blair | Myles R Minter | Strong Buy | Hold |
10/31/2023 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
10/31/2023 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
10/26/2023 | Raymond James | Danielle Brill | Strong Buy | Strong Buy |
10/18/2023 | Exane BNP Paribas | Victor Floch | Not Available | Strong Buy |
7/28/2023 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
6/15/2023 | Societe Generale | Justin S Smith | Not Available | Strong Sell |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.62 |
ABR (Last week) | 1.62 |
# of Recs in ABR | 26 |
Average Target Price | $501.35 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 252 |
Current Quarter EPS Est: | -0.79 |